GDI2P1: A Protein Linked To Cancer and Cell Division (G2667)

Target Name: GDI2P1

NCBI ID: G2667

GDI2P1

Other Name(s): GDP dissociation inhibitor 2 pseudogene 1 | GDI2P

GDI2P1: A Protein Linked To Cancer and Cell Division

GDI2P1, also known as GDP dissociation inhibitor 2 pseudogene 1, is a protein that is expressed in various tissues and cells in the human body. It is a key regulator of the cell division process, and its levels have been linked to various diseases, including cancer.

GDI2P1 is a member of the GDP dissociation inhibitor (GDI) family, which is a group of proteins that play a critical role in preventing protein-protein interactions that can lead to aggregation and other toxic effects. The GDI family has been identified as a potential drug target for various diseases, including cancer.

GDI2P1 is expressed in a variety of tissues, including the brain, heart, and liver. It is highly expressed in the liver, which is a major site of protein synthesis and degradation. GDI2P1 is also expressed in the plasma, which is the body's circulation systems, and in various cell types, including neurons and leukemia cells.

GDI2P1 has been shown to play a critical role in regulating cell division and cell signaling processes. It is a key regulator of the G1/S transition, which is a critical step in the cell division process. GDI2P1 is also involved in the regulation of the G2/M transition, which is another critical step in cell division.

GDI2P1 has been linked to various diseases, including cancer. Studies have shown that high levels of GDI2P1 are associated with an increased risk of cancer, particularly breast and ovarian cancers. This is because GDI2P1 plays a critical role in regulating cell division and cell signaling processes , and changes in these processes can lead to the formation of cancer cells.

In addition to its role in cell division, GDI2P1 is also involved in the regulation of various signaling pathways that are important for cell survival and growth. One of these signaling pathways is the PI3K/Akt signaling pathway, which is involved in the regulation of cell signaling processes that are important for cell survival and growth.

GDI2P1 is a potential drug target for various diseases, including cancer. Studies have shown that inhibiting GDI2P1 can lead to the inhibition of cell division and cell signaling processes, which can lead to the formation of cancer cells. Additionally, inhibiting GDI2P1 has been shown to reduce the risk of cancer in cell models that are relevant to human cancer.

In conclusion, GDI2P1 is a protein that is expressed in various tissues and cells in the human body. It is a key regulator of the cell division process and has been linked to various diseases, including cancer. inhibiting GDI2P1 may be a promising strategy for the treatment of cancer and other diseases. Further research is needed to fully understand the role of GDI2P1 in cell division and cell signaling processes, as well as its potential as a drug target.

Protein Name: GDP Dissociation Inhibitor 2 Pseudogene 1

The "GDI2P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GDI2P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets